Thiogenesis Therapeutics, Corp.
Financial Statements (IFRS) · Amounts in CAD
Income Statement
Balance Sheet
Cash Flow
| Line Item | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 | Q4 2024Dec 31, 2024 | Q3 2024Sep 30, 2024 | Q2 2024Jun 30, 2024 |
|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Selling General And Administration | 471,840 | 368,800 | 321,538 | 537,967 | 272,925 | -- |
| General And Administrative Expense | 471,840 | 368,800 | 321,538 | 537,967 | 272,925 | -- |
| Research And Development | 1.9M | 1.5M | 1.1M | 778,491 | 404,857 | -- |
| Operating Expense | 2.4M | 1.8M | 1.4M | 1.3M | 677,782 | -- |
| Operating Income | -2.4M | -1.8M | -1.4M | -1.3M | -677,782 | -- |
| EBIT | -2.4M | -1.8M | -1.4M | -1.3M | -677,782 | -- |
| Interest Income | 6,450 | 11,010 | 26,846 | 34,391 | 48,617 | -- |
| Interest Income Non Operating | 6,450 | 11,010 | 26,846 | 34,391 | 48,617 | -- |
| Net Interest Income | 6,450 | 11,010 | 26,846 | 34,391 | 48,617 | -- |
| Other Income Expense | 4,001 | -75,789 | -2,447 | 155,086 | -27,691 | -- |
| Gain On Sale Of Security | 4,001 | -75,789 | -2,447 | 155,086 | -27,691 | -- |
| Pretax Income | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Net Income From Continuing And Discontinued Operation | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Income From Continuing Operation Net Minority Interest | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Income Including Noncontrolling Interests | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Income Common Stockholders | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Income | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| EBITDA | -2.4M | -1.8M | -1.4M | -1.3M | -677,782 | -- |
| Normalized EBITDA | -2.4M | -1.8M | -1.4M | -1.5M | -650,091 | -- |
| Basic EPS | -0.05 | -0.04 | -0.03 | -- | -0.01 | -0.01 |
| Diluted EPS | -0.05 | -0.04 | -0.03 | -- | -0.01 | -0.01 |
| Basic Average Shares | 50.1M | 46.3M | 46.0M | -- | 45.5M | 45.5M |
| Diluted Average Shares | 50.1M | 46.3M | 46.0M | -- | 45.5M | 45.5M |
| Total Unusual Items | 4,001 | -75,789 | -2,447 | 155,086 | -27,691 | -- |
| Total Unusual Items Excluding Goodwill | 4,001 | -75,789 | -2,447 | 155,086 | -27,691 | -- |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Income | -2.4M | -1.8M | -1.4M | -1.3M | -629,165 | -- |
| Diluted NI Availto Com Stockholders | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Income Continuous Operations | -2.4M | -1.9M | -1.4M | -1.1M | -656,856 | -- |
| Net Non Operating Interest Income Expense | 6,450 | 11,010 | 26,846 | 34,391 | 48,617 | -- |
| Other Gand A | 213,992 | 226,418 | 173,970 | 394,302 | 213,585 | -- |
| Salaries And Wages | 257,848 | 142,382 | 147,568 | 143,665 | 59,340 | -- |
| Total Expenses | 2.4M | 1.8M | 1.4M | 1.3M | 677,782 | -- |
| Line Item | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 | Q4 2024Dec 31, 2024 | Q3 2024Sep 30, 2024 | Q2 2024Jun 30, 2024 |
|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | 3.5M | 1.8M | 3.0M | 3.8M | 4.1M | -- |
| Cash Cash Equivalents And Short Term Investments | 3.5M | 1.8M | 3.0M | 3.8M | 4.1M | -- |
| Accounts Receivable | -- | 48,556 | 57,233 | 2,613 | 17,076 | 1,324 |
| Receivables | 68,123 | 48,556 | 57,233 | 87,928 | 73,542 | -- |
| Prepaid Assets | 54,919 | 48,349 | 61,429 | 47,596 | 33,000 | -- |
| Current Assets | 3.6M | 1.9M | 3.1M | 4.0M | 4.3M | -- |
| Total Non Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Total Assets | 3.6M | 1.9M | 3.1M | 4.0M | 4.3M | -- |
| Payables And Accrued Expenses | 1.5M | 1.5M | 993,585 | 557,876 | 105,921 | -- |
| Current Liabilities | 1.5M | 1.5M | 993,585 | 557,876 | 105,921 | -- |
| Total Non Current Liabilities Net Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Total Liabilities Net Minority Interest | 1.5M | 1.5M | 993,585 | 557,876 | 105,921 | -- |
| Common Stock | 19.9M | 16.2M | 16.2M | 16.1M | 15.7M | -- |
| Capital Stock | 19.9M | 16.2M | 16.2M | 16.1M | 15.7M | -- |
| Retained Earnings | -20.0M | -17.6M | -15.7M | -14.3M | -13.2M | -- |
| Gains Losses Not Affecting Retained Earnings | 2.2M | 1.8M | 1.6M | 1.6M | 1.6M | -- |
| Other Equity Adjustments | 2.2M | 1.8M | 1.6M | 1.6M | 1.6M | -- |
| Common Stock Equity | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Stockholders Equity | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Total Equity Gross Minority Interest | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Total Capitalization | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Net Tangible Assets | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Tangible Book Value | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Working Capital | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Invested Capital | 2.2M | 456,835 | 2.1M | 3.4M | 4.1M | -- |
| Share Issued | 51.8M | 46.3M | 46.3M | 46.0M | 45.5M | -- |
| Ordinary Shares Number | 51.8M | 46.3M | 46.3M | 46.0M | 45.5M | -- |
| Taxes Receivable | 68,123 | -- | -- | 85,315 | 56,466 | 46,236 |
| Line Item | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 | Q4 2024Dec 31, 2024 | Q3 2024Sep 30, 2024 | Q2 2024Jun 30, 2024 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.1M | -1.2M | -829,859 | -538,575 | -834,897 | -- |
| Cash Flow From Continuing Operating Activities | -2.1M | -1.2M | -829,859 | -538,575 | -834,897 | -- |
| Stock Based Compensation | 297,663 | 215,632 | 128,405 | 165,433 | 36,973 | -- |
| Change In Working Capital | -37,742 | 511,717 | 452,571 | 422,973 | -215,013 | -- |
| Changes In Account Receivables | -19,567 | 8,677 | 30,695 | -14,386 | -25,982 | -- |
| Change In Receivables | -19,567 | 8,677 | 30,695 | -14,386 | -25,982 | -- |
| Change In Payables And Accrued Expense | -11,605 | 489,960 | 435,709 | 451,955 | -202,531 | -- |
| Financing Cash Flow | 3.8M | 0.00 | 0.00 | 253,900 | 7,000 | -- |
| Cash Flow From Continuing Financing Activities | 3.8M | 0.00 | 0.00 | 253,900 | 7,000 | -- |
| Effect Of Exchange Rate Changes | -28,862 | 1,076 | -3,512 | -14,472 | 4,685 | -- |
| Changes In Cash | 1.7M | -1.2M | -829,859 | -284,675 | -827,897 | -- |
| Beginning Cash Position | 1.8M | 3.0M | 3.8M | 4.1M | 5.0M | -- |
| End Cash Position | 3.5M | 1.8M | 3.0M | 3.8M | 4.1M | -- |
| Free Cash Flow | -2.1M | -1.2M | -829,859 | -538,575 | -834,897 | -- |
| Change In Prepaid Assets | -6,570 | 13,080 | -13,833 | -14,596 | 13,500 | -- |
| Net Income From Continuing Operations | -2.4M | -1.9M | -1.4M | -1.1M | -656,857 | -- |
| Proceeds From Stock Option Exercised | 0.00 | 0.00 | 0.00 | 253,900 | 7,000 | -- |